2023 World Conference on Lung Cancer (Posters)-P1.03. Combinationof Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment

P1.03. Combinationof Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment - PDF(Slides)

Back to course

Pdf Summary

In this study, the researchers aimed to investigate the effects of combining the immunotherapy drug Tislelizumab with the antiangiogenic drug Anlotinib on lung adenocarcinoma. They explored the mechanisms of action of this combination therapy on immune cells, cytokines, intestinal flora, metabolomics, and transcriptomics.<br /><br />The results showed that the combination treatment group exhibited slower tumor growth compared to the monotherapy groups. The levels of IL-2 and IFN-γ (cytokines) in the serum of mice in the combination treatment group were increased, and the number of CD4 T and CD8 T cells in tumor tissues was significantly higher. Additionally, the expression levels of VEGF, CD31, CD34, and MVD were lower in the combination treatment group than in the Tislelizumab monotherapy group.<br /><br />The researchers also observed changes in the intestinal microbial microenvironment in the combination therapy group. The microbial microbiota richness of mice in this group decreased, and specific flora such as Rikenellaceae, Verrucomicobia, Verrucomicrobiaceae, and Akkermansia increased.<br /><br />Furthermore, the combination therapy affected various metabolic pathways involved in glucose metabolism, vitamin absorption, and mTOR signaling. They identified six important metabolic markers in the intestinal tissues of mice in the combination group.<br /><br />The study also found that the combination therapy had a stronger anti-tumor effect compared to single-drug groups. The mechanism behind this effect was related to the interferon-γ response and RNA metabolism. The researchers identified key genes such as Mmp9 and Plaur, and further analysis revealed that higher expression levels of Plaur weakened its tumor suppressive effect.<br /><br />Overall, this study provides insights into the specific mechanisms and effects of combining Tislelizumab and Anlotinib for lung adenocarcinoma. The findings suggest potential strategies for individualized and comprehensive treatment in clinical settings.

Asset Subtitle

Yuanliu Nie

Meta Tag

Speaker Yuanliu Nie

Topic Tumor Biology: Preclinical Biology - Omics Approaches

Keywords

immunotherapy

Tislelizumab

Anlotinib

lung adenocarcinoma

cytokines

intestinal flora

metabolomics

transcriptomics

tumor growth

anti-tumor effect